Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 13, 2016Cancer Immunology ResearchOpen Access

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

View Full Paper
Ask AI
Bookmark
Share

Authors

Jeffrey S. Weber
Jeffrey S. WeberNYU Langone HealthGGGeoffrey T. GibneyGeorgetown UniversityRKRagini R. KudchadkarDaiichi Sankyo (Germany)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Weber et al. (2016) studied this question.

synapsesocial.com/papers/6a20d07cf76165bc1becaed6https://doi.org/10.1158/2326-6066.cir-15-0193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes2015 · 892 citations
  2. 2Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production2013 · 141 citations
  3. 3Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria2009 · 3,284 citations
  4. 4Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab2014 · 2,243 citations
  5. 5Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma2015 · 8,288 citations